Change in Management

October 31, 2026 BSE Limited Code: 532321 National Stock Exchange of India Limited Code: Zyduslife P J Towers, Exchange Plaza, C/1, Block G, Bandra-Kurla Dalal Street, Complex, Bandra (East), Mumbai-400001 Mumbai-400051 Re.: Changes in Senior Management team Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) read with SEBI Master Circular dated January 30, 2026 (“the SEBI Master Circular”) Dear Sir / Madam, This is to inform that Dr. Amrut Naik, President and Business Unit Head, International Markets Business has resigned on October 31, 2026, and he will be relieved from his duties on November 7, 2026, and in view of the same, he will cease to be the part of Senior Management team. The copy of his resignation letter is attached as Annexure-“1”. Further, based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Christoph Stoller as President and Business Unit Head, International Markets Business and he will be part of the Senior Management team. Necessary details as stipulated under regulation 30 of the Listing Regulations read with the SEBI Master Circular are provided in Annexure-“2”. Please find the same in order. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Annexure-"1" Date: October 31, 2026 Dr. Sharvil P. Patel The Managing Director Zydus Lifesciences Limited Subject: Resignation Dear Sir, I hereby tender my resignation from my position with Zydus Lifesciences Limited with a request to be relieved on November 7, 2026. My association with Zydus has been professionally enriching and personally rewarding. I am deeply grateful for the opportunities, trust, support, and guidance extended to me during my tenure with the Company. Working alongside exceptional colleagues and contributing to the growth and success of the organization has been a matter of immense pride and satisfaction. I take this opportunity to express my sincere appreciation to you and the leadership team for your encouragement and confidence in me over the years. The experience and learning gained at Zydus will remain invaluable throughout my professional journey. I wish Zydus Lifesciences Limited continued growth, success, and global recognition in the years ahead. Thank you once again for the opportunity to be a part of this remarkable organization. Yours sincerely, Dr. Amrut Naik Annexure-“2” Sr. Particulars Resignation Appointment 1. Name Dr. Amrut Naik Mr. Christoph Stoller 2. Reason for change viz. Resignation Appointment appointment, re- appointment, resignation, removal, death or otherwise; 3. Date of appointment / re- Not applicable Date of appointment: appointment / cessation (as November 2, 2026 applicable) & term of appointment / re-appointment; Term of appointment: full time employment 4. Brief profile (in case of Not applicable Attached as Annexure-“3”. appointment) 5. Disclosure of relationship Not applicable Not applicable between directors (in case of appointment of a director) For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Annexure-“3”-Brief profile of Mr. Christoph Stoller Mr. Christoph Stoller is a highly accomplished Swiss pharmaceutical industry leader with more than 30 years of global experience in branded pharmaceuticals, specialty medicines, biologics, biosimilars, generics, OTC products, and innovative therapies. He has held CEO, President, Board, and Global Business Leadership roles across Europe, Emerging Markets, LATAM, and APAC. Educational qualification: Degree in Business Administration, Economics, Law, and Social Sciences from the University of St. Gallen, Switzerland, one of Europe's most respected business schools. Previous role  President & Business Head (EMEA, LATAM & APAC) at Glenmark Pharmaceuticals.  Member of Glenmark's Global Leadership Team.  Leading approximately 2,000 employees across 80 countries with P&L responsibility exceeding USD 750 million. Major Career Highlights  Doubled European revenue at Glenmark from approximately USD 200 million and significantly improved EBITDA performance.  Led commercialization and expansion of innovative products across international markets.  Member of Glenmark's AI Steering Committee driving business transformation initiatives. Previous leadership roles Teva Pharmaceuticals (2011-2021)  Senior Vice President & Cluster General Manager, Germany & Austria.  Senior Vice President, Generics & Commercial Operations Europe.  Managed businesses with up to USD 2 billion P&L and around 2,700 employees.  Led the European integration of Teva's acquisition of Actavis.  Delivered major profitability improvements, market access initiatives, and large-scale transformation programs. Helvepharm AG  CEO and member of the Executive Committee of Zur Rose Group.  Successfully transformed the company from a loss-making business into a highly profitable organization with strong value creation. Earlier Career Leadership roles at Roche Pharma, DSM Nutritional Products, and Swiss Re. Industry Leadership & Governance  Former President of Medicines for Europe (2019-2021), the leading European association representing generic and biosimilar medicine companies responsible for supplying approximately 70% of medicines in Europe.  Held Vice President and Executive Committee positions within the same organization.  Former Vice Chairman of Progenerika (Germany) and Board Member of Intergenerika (Switzerland). Education.